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Abstract
Background: Dengue fever is the most important vector-borne viral disease. Four serotypes of dengue virus,
DENV1 to DENV4, coexist. Infection by one serotype elicits long-lasting immunity to that serotype but not the other
three. Subsequent infection by a different serotype is a risk factor for severe dengue. Domain III (ED3) of the viral
envelope protein interacts with cell receptors and contains epitopes recognized by neutralizing antibodies. We
determined the serotype specificity and cross-reactivity of human IgMs directed against ED3 by using a well-
characterized collection of 90 DENV-infected and 89 DENV-uninfected human serums.
Methods: The recognitions between the four serotypes of ED3 and the serums were assayed with an IgM
antibody-capture ELISA (MAC-ELISA) and artificial homodimeric antigens. The results were analyzed with Receiving
Operator Characteristic (ROC) curves.
Results: The DENV-infected serums contained IgMs that reacted with one or several ED3 serotypes. The
discrimination by ED3 between serums infected by the homotypic DENV and uninfected serums varied with the
serotype in the decreasing order DENV1 > DENV2 > DENV3 > DENV4. The ED3 domain of DENV1 gave the highest
discrimination between DENV-infected and DENV-uninfected serums, whatever the infecting serotype, and thus
behaved like a universal ED3 domain for the detection of IgMs against DENV. Some ED3 serotypes discriminated
between IgMs directed against the homotypic and heterotypic DENVs. The patterns of cross-reactivities and
discriminations varied with the serotype.
Conclusions: The results should help better understand the IgM immune response and protection against DENV
since ED3 is widely used as an antigen in diagnostic assays and an immunogen in vaccine candidates.
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Background
Dengue is a mosquito-borne infection of the tropics and
subtropics. Some 2.5 billion people are at risk, and 50–
100 millions are infected annually. Most infections are
either asymptomatic or result in dengue fever, a relatively
mild illness. However, a life threatening form, severe den-
gue, develops in 1–5% of infections [1].
Dengue viruses have been divided into four serotypes,
differing in overall amino acid sequence by ≥30% [2].
Infection by DENV raises lifelong immunity against the
infecting serotype but only transient protection against
the other serotypes [3]. Subsequent infections by viruses
from different DENV serotypes are associated with a
greater risk for severe dengue [4]. The preferential re-
activation of the memory B and T cells that correspond
to a primary infection, and an antibody-dependent en-
hancement (ADE) of infection constitute triggering mech-
anisms of severe dengue during a secondary infection by a
different viral serotype [5,6].
The IgMs are the first antibodies to appear after a pri-
mary DENV infection [7,8]. Murine and simian IgMs have
been shown to neutralize DENV in vitro and be devoid of
ADE activity [9,10]. The IgMs play a role in the immune
response after a vaccination by a live attenuated DENV
and a challenge by the homotypic virus in monkeys. The
immunized animals exhibit an earlier increase of the IgM
response than control animals and there is evidence for an
anamnestic IgM response [11,12]. A similar observation
has been made for monkeys vaccinated with a recombin-
ant domain III of the viral envelope protein [13,14] (see
below).
Immunochemical assays are commonly used to detect
DENV-specific IgM and IgG antibodies. Because high
affinity IgGs can compete with IgMs for antigen binding,
especially during a secondary infection, an IgM capture
assay is preferably used. In an IgM antibody-specific cap-
ture ELISA (MAC-ELISA), the virus specific IgMs in the
test human serum are detected by first capturing all the
serum IgMs through antibodies that are specific to human
IgMs and bound to a solid phase [15]. The serotype speci-
ficity and cross-reactivity of the MAC-ELISA assays have
been studied with various forms of viral antigen: extracts
of suckling mouse brains (SMB) infected with DENV, cul-
ture supernatants of mammalian Vero cells or insect C6/
36 cells infected with DENV; non-infectious virus-like
particles (VLP). These studies have shown that the IgM
response is serotype cross-reactive [15-18]. With SBM
extracts, some monotypic responses may be observed but
they frequently do not correlate with the virus serotype
isolated from a patient [19]. With cell culture supernatants
in contrast, the highest response is always obtained for the
infecting serotype [16,17].
The dengue viruses are enveloped RNA viruses. The
structures of the whole virus and of its envelope (E)
protein have been solved by electron cryo-microscopy
and X-ray crystallography, with the E protein either in a
free state or in complex with an antibody [20-24]. Ninety
dimers of the E protein cover the surface of the virus.
Each E protein monomer comprises three ectodomains,
ED1 to ED3, and a transmembrane segment. ED2 in-
cludes the dimerization interface, glycosylation sites and
the peptide of fusion with the cellular membrane. ED3 is
continuous and comprises residues 296–400 of the E
protein (DENV1 numbering). Its fold is compact,
immunoglobulin-like and stabilized by a disulfide bond
between residues Cys302 and Cys333. The structures of
recombinant ED3 domains have been solved by X-ray
crystallography or NMR methods, either in a free state
or in complex with an antibody [25-33]. The structure of
the isolated ED3 domain is close to its structure in the E
protein.
The ED3 domain participates in the interaction between
the virus and primary or secondary cell receptors, includ-
ing heparan sulfates and ribosomal protein SA [34-41].
Consistently, recombinant ED3 domains from DENV1
and DENV2 inhibit infectivity of the cognate virus [36,
42-44]. Mutations in the ED3 domain of DENV2 affect its
cell tropism and virulence [45]. The ED3 domain contains
epitopes for neutralizing IgM antibodies [46]. IgM anti-
bodies to ED3 in human serums constitute a large fraction
of the total IgMs to the E protein in both primary and sec-
ondary immune responses. In contrast, IgG antibodies to
ED3 constitute only a small fraction of the total IgGs to
the E protein [47,48].
ED3 domains have been used as antigen in indirect IgM
or IgG ELISA to detect infections by DENV [49-51]. Many
studies have shown that the isolated ED3 domains from
the four DENV serotypes are immunogenic in mice and
elicit neutralizing and protective antibodies [52-56]. The
ED3 domain from DENV2 (ED3.DENV2) elicits neutraliz-
ing antibodies and partial protection in monkey against
the cognate virus [56]. Multivalent ED3 domains, i.e. sin-
gle polypeptides including the ED3 domains from several
serotypes of DENV, elicit neutralizing and protective anti-
bodies in mice simultaneously to the corresponding DENV
serotypes [57-59]. Recombinant or synthetic genes coding
for a single or several ED3 domains in tandem have been
inserted in the genome of infective non-pathogenic viruses
and shown to elicit neutralizing antibodies in mice,
e.g. using adenovirus or measle vaccine virus as vectors
[60-62].
Here, given the importance of the ED3 domain for the
life cycle of the virus and for diagnostic and vaccinal
applications, we analyzed the cross-reactivities between
the IgMs of human patients infected by any one of the
four DENV serotypes and the ED3 domains from the
four serotypes in MAC-ELISA assays. We used dimeric
hybrids, (H6-ED3-PhoA)2, as antigens; they included a
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hexahistidine tag, an ED3 domain and an improved E.
coli alkaline phosphatase. We assayed human serums
whose infectious status had been carefully established.
We analyzed the results of the MAC-ELISAs with Re-
ceiver Operating Characteristic (ROC) curves because
they provide a global parameter, the accuracy of the test,
that does not depend on the choice of a threshold in the
test. These analyses gave statistical data on the capacity
of the ED3 domain of each serotype: i) to distinguish
between human serums infected by one of the DENV sero-
types and uninfected serums; and ii) to distinguish between
serums infected by a homotypic DENV and serums
infected by a heterotypic DENV. They also gave data on
the serotypes of the ED3 domain that are recognized by
the IgMs of a serum infected by a given DENV serotype.
The results showed that each viral serotype generated a
specific pattern of specificity and cross-reactivity.
Methods
Reagents and buffers
PBS (phosphate buffered saline), Tween 20, 4-nitrophenyl
phosphate (pNPP) and goat antibodies to human IgMs
were purchased from Sigma-Aldrich; bovine serum albu-
min (BSA) from Roche; low-fat milk powder from Regilait;
Maxisorp ELISA plates from NUNC. Buffer A contained
0.1% Tween 20 in PBS; buffer B, 5% (w/v) low-fat milk
powder in buffer A; buffer C, 1% (w/v) low-fat milk pow-
der in buffer A; buffer D, 10% diethanolamine, pH 9.8,
10 mMMgSO4, 20 μM ZnCl2.
Bacterial, plasmid and viral strains
The plasmids encoding the H6-ED3-PhoA hybrids have
been described [41]. Table 1 gives the origin of the viral
ED3 domain and the corresponding segment of the enve-
lope protein. Table 2 gives the number of residue changes
between the ED3 domains of any two DENV serotypes,
and also between the ED3 domain of any DENV serotype
and the consensus ED3 domain (DENVc) [63,64]. The
productions of the H6-ED3-PhoA hybrids in the periplas-
mic space of E. coli and their purification from periplasmic
extracts through their His-tag were performed essentially
as described [41]. The fractions of purification were ana-
lyzed by SDS-PAGE in reducing conditions. The purest
fractions were pooled, snap-frozen and kept at −80°C.
They were homogeneous at >95%.
Clinical samples
A first set of human serums (Group 1) was collected
within the normal activity of the National Reference
Center (NRC) for Arboviruses, Institut Pasteur de la
Guyane, French Guiana. These serums were collected
from patients who displayed clinical symptoms of dengue
and whose infection by DENV was confirmed by labora-
tory methods. A second set of human serums (Group 2)
was collected in the context of a clinical study
(DENFRAME project) that was performed in French
Guiana [65]. These serums were collected from patients
who displayed clinical symptoms of dengue but were diag-
nosed as negative for DENV infection. In the following,
we designate these serums as DENV-uninfected serums.
Both Group 1 and Group 2 serums consisted of a series of
blood samples collected for the first one during the
viremic phase of the disease (from day 0 to day 4 after
fever onset) and for a second one during the early con-
valescent phase (day 5 or later). The samples were
characterized by standard diagnostic methods that
included virus isolation on mosquito cells and/or viral
RNA detection by RT-PCR, non-structural NS1 protein
detection, as well as MAC-ELISA and IgG-specific indirect
ELISA using virus-infected suckling mouse brain (SMB) ex-
tracts as antigens. For the serums of Group 1, the DENV
serotype that was responsible for the disease, was identified
by RT-PCR and the presence of IgMs against the infecting
DENV serotype was ascertained from a MAC-ELISA that
used the corresponding SMB extract as antigen. None of
the serums was infected simultaneously by two or more
DENV serotypes. The serums of Group 1 scored as positive
for IgG to DENV in an indirect ELISA performed on an
additional sample collected during the convalescent phase
of the disease (day 15 or later). For the serums of Group 2,
all the tests were negative. The methodologies for the col-
lection of the serum samples, the collection of the associ-
ated clinical data, and the characterization of the serums
have been described previously in detail [65]. Data on the
primary or secondary nature of the infection were not avail-
able. We obtained informed consent from the patients for
Table 1 Viral origins of the (H6-ED3-PhoA)2 dimers
Virus Strain Genbank No E residues
DENV1 FGA/89 AF226687 295-400
DENV2 Jamaica/N.1409 M20558 295-400
DENV3 PaH881/88 AF349753 293-398
DENV4 ThD4-0113-76 AY618949 295-400
The last column gives the residues of the viral E protein present in the
H6-ED3-PhoA hybrid. The codons in the recombinant genes were synonymous
but not necessarily identical with those in the original viral genomes.
Table 2 Number of residue changes between ED3
domains of different serotypes
Serotype DENV1 DENV2 DENV3 DENV4 DENVc
DENV1 0 37 31 47 22
DENV2 37 0 42 41 25
DENV3 31 42 0 51 27
DENV4 47 41 51 0 32
DENVc 22 25 27 32 0
DENVc, consensus ED3 domain.
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the use of the Group 2 serum samples in a previous clinical
study, as described [65]. The constitution of the above
human serum collections (Group 1 and Group 2) and their
use for the present study were approved by the Institutional
Review Board of Institut Pasteur and a regional ethical
committee (Comité de Protection des Personnes, Ile-de-
France 1).
MAC-ELISA
The MAC-ELISAs of the present study were performed
in 96-well flat-bottom microtiter plates with a volume of
100 μL/well. The plates were sensitized with antibodies
to human IgMs as follows. A goat antibody to human
IgMs (1.0 μg/mL in PBS) was loaded in the wells of the
plate. The plate was incubated overnight at 4°C for the
reaction of adsorption. The wells were washed with buf-
fer A (three times), blocked with buffer B for 1 h at 37°C,
and then washed as above. The serums and recombinant
antigens were diluted in buffer C. The serums were di-
luted 100-fold, a dilution at which they nearly saturate the
IgM binding sites in the sensitized wells [66]. Wells were
loaded with the diluted serums or with buffer C as a blank
sample, and the plate was incubated for 1 h at 37°C for
the reaction of antibody capture. The wells were washed
as above and then loaded with the solution of recombin-
ant antigen. The plate was incubated for 1 h at 37°C for
the binding reaction. The wells were washed as above and
the bound antigen, (H6-ED3-PhoA)2, was detected by
addition of 5 mM pNPP in buffer D and measurement of
A405nm after 3 h at 25°C. Each experimental data point
was performed at least in duplicate and the corresponding
signals were averaged. The serum specific signal was
obtained by subtracting the signal of the blank sample
from the signal of the serum sample.
Analysis of the experimental data
The curve fits were performed with Kaleidagraph (Synergy
Software), which gives Pearson’s coefficient of correlation,
RP. The mean values, standard deviations (SD) and stand-
ard errors (SE) were calculated with the same program.
The results of the MAC-ELISAs were analyzed through
ROC curves, which are equivalent to Wilcoxon statistics
[67,68]. A ROC curve relates the False Positive Fraction
(FPF = 1 - specificity) to the True Positive Fraction (sensi-
tivity) of a test when the threshold varies. The area under
the ROC curve (AUC) is an unbiased measure of the test
accuracy and the difference AUC - 0.5 is the discrimin-
ation power or more simply discrimination of the test. An
AUC value of 1.0 represents a perfect test whereas a value
of 0.5 represents a worthless test. A rough guide for classi-
fying the accuracy of a test has been proposed: 0.90-1.0 =
excellent, 0.80-0.90 = good, 0.70-0.80 = fair, 0.60-0.70 =
poor, 0.50-0.60 = fail. Semi-parametric ROC curves were
computed with the LABROC4 program [69] as imp-
lemented in the Web based calculator JLABROC4 [70].
Results
Rationale
To analyze the serotype specificities and cross-reactivities
of IgMs directed against the ED3 domains of the dengue
viruses, we used a collection of 179 well-characterized
human serums (see Methods). These serums belonged to
two groups. The first group included four categories of
infected serums, i.e. 18 serums infected by DENV1, 24 by
DENV2, 18 by DENV3 and 30 by DENV4 respectively, for
a total of 90 DENV-infected serums. Samples of these ser-
ums reacted positively in a MAC-ELISA that used a whole
homotypic DENV antigen. The second group contained
89 DENV-uninfected serums. In a first step, we assayed
each of the 179 serums in duplicate in four MAC-ELISAs
that used four (H6-ED3-PhoA)2 dimers as antigens. The
ED3 domains of these four reagents came from each of
the four serotypes of DENV and we will designate these
reagents as R1 to R4 in the following. The mean signal
values and associated SD and SE of the MAC-ELISAs
performed with R1 to R4 on the five categories of serums
above are reported in Table 3. In a second step, we com-
bined the serums in different sets that we considered as
positive (+) or negative (−) for the hypothesis under test
and analyzed the results of the MAC-ELISAs with ROC
curves. More specifically, we derived a unique parameter
for each test from these analyses, the precision (AUC) or
discrimination (AUC – 0.5), and compared them between
tests.
Table 3 Mean signals of MAC-ELISAs performed with
(H6-ED3-PhoA)2 dimers on five categories of serums
Serum # R1 R2 R3 R4
DENV1 18 1.3 0.7 0.3 0.06
± 1.4 (0.3) ± 1.1 (0.2) ± 0.5 (0.1) ± 0.04 (0.01)
DENV2 24 0.07 0.5 0.11 0.038
± 0.09 (0.02) ± 0.5 (0.1) ± 0.14 (0.03) ± 0.020
(0.004)
DENV3 18 0.08 0.19 0.23 0.04
± 0.11 (0.03) ± 0.20 (0.05) ± 0.21 (0.05) ± 0.09 (0.02)
DENV4 30 0.06 0.08 0.061 0.11
± 0.16 (0.03) ± 0.09 (0.02) ± 0.049
(0.009)
± 0.22 (0.04)









R1 to R4, (H6-ED3-PhoA)2 dimers of serotypes DENV1 to DENV4, respectively.
The first and second columns give the serotype of the infecting DENV and the
number of samples for each category of serums. None, DENV-uninfected
serums. The other entries give the mean A405nm value and associated SD and
SE (in parentheses) for MAC-ELISAs performed on the serums of the first
column with reagents R1 to R4.
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Discrimination between DENV-infected and -uninfected
serums
In a first step, we analyzed the capacity of the four re-
agents, R1 to R4, to discriminate between IgMs of patients
infected by a DENV serotype, either homotypic or hetero-
typic to the reagent, and IgMs of DENV-uninfected pa-
tients. The serums of the infected patients were considered
as positive and the serums of the uninfected patients as
negative. The discrimination between the IgMs of the
infected serums and the IgMs of the uninfected serums
was the highest when the reagent and infecting DENV
were homotypic. These homotypic discriminations were
excellent for DENV1, good for DENV2, fair for DENV3
and poor for DENV4 (diagonal of Table 4). Therefore, the
serums of patients infected by any of the DENV viruses
formed IgMs against the homotypic ED3 domain and
could be recognized by the homotypic reagent.
Reagent R1 discriminated between the IgMs of DENV2-,
DENV3- or DENV4-infected serums and IgMs of DENV-
uninfected serums with excellent (DENV2), good (DENV3)
or fair (DENV4) accuracies (column 1 of Table 4). There-
fore, the IgMs of serums infected by DENV2, DENV3 or
DENV4 cross-reacted with the ED3 domain from DENV1
(ED3.DENV1). By a similar reasoning, we concluded that
the IgMs of serums infected by DENV1 or DENV3 cross-
reacted with ED3.DENV2 but not the IgMs of serums
infected by DENV4 (column 2 of Table 4). The IgMs of
serums infected by heterotypic DENV did not cross-react
significantly with ED3.DENV3 and ED3.DENV4 (columns
3 and 4 of Table 4). We concluded that there exist inhe-
rent cross-reactivities between the ED3 domain of a given
DENV serotype and the human IgMs directed against
DENV heterotypes.
Relation between reagent serotype and test accuracy
Table 4 enabled us to compare the accuracies of MAC-
ELISAs performed with R1 to R4 when run on the same
two sets of serums, infected and uninfected. For ex-
ample, the discrimination between the DENV1-infected
serums and the DENV-uninfected serums was excellent
for R1, good for R2, poor for R3 and nil for R4 (row 1 of
Table 4). Similarly, the discrimination between the
DENV2-infected and DENV-uninfected serums was ex-
cellent for R1 and R2 and nil for R3 and R4 (row 2 of
Table 4). The discrimination between DENV3-infected
and DENV-uninfected serums was good for R1, fair for
R2 and R3, and nil for R4 (row 3 of Table 4). The dis-
crimination between DENV4-infected and DENV-
uninfected serums was fair for R1, nil for R2 and R3 and
poor for R4 (row 4 of Table 4). The discrimination be-
tween DENVj-infected serums and DENV-uninfected
serums by the Ri reagent was not linearly correlated with
the number ni,j of residue changes between ED3.DENVi
and ED3.DENVj (i ≠ j) (RP = 0.54). These comparisons
suggested that the levels of discrimination depended on
the specific couple of DENV serotypes and not on the
sequence differences between the heterotypic ED3 do-
mains. Whether and how the levels of discrimination of
the same two sets of (+) and (−) serums by the different
reagents might be related to the strengths of the IgMs
reactivities is considered in the Discussion section.
The homotypic Ri reagent and some heterotypic Rj re-
agents could discriminate between DENVi-infected ser-
ums and DENV-uninfected serums (i ≠ j). How did these
homotypic and heterotypic discriminations compare? The
discriminations by R1 were higher than or equal to those
by the homotypic reagents for any infecting serotype,
DENV2, DENV3 or DENV4 (compare the numbers in
column 1 and in the diagonal of Table 4). The discrimi-
nations by R2 were roughly equal to those by the
homotypic reagents in the same conditions. In contrast,
R3 and R4 did not recognize serums that were infected
by heterotypic DENVs. These results were not due to
the serums and their IgMs since the serums were iden-
tical for the four reagents. They were necessarily due to
differences in the antigenic properties of the ED3
domains of the four DENV serotypes since the (H6-
ED3-PhoA)2 constructions were exactly identical except
for this domain.
Discriminations between DENV serotypes
In a second step, we analyzed the accuracy with which a
given Ri reagent discriminated between DENVi- and
DENVj-infected serums, with i ≠ j (Table 5). The R1 re-
agent discriminated between the DENV1-infected ser-
ums and the DENV2-, DENV3- or DENV4- infected
serums with good accuracies (column 1 of Table 5),
despite important cross-reactions between ED3.DENV1
and the IgMs of serums infected by heterotypic DENVs
(column 1 of Table 4). The R2 reagent discriminated
between DENV2-infected serums and either DENV3- or
DENV4-infected serums with fair to good accuracies but
it did not discriminate between DENV2- and DENV1-
Table 4 Capacity of the (H6-ED3-PhoA)2 reagents
to discriminate between DENV-infected and
DENV-uninfected serums in a MAC-ELISA
(+) Serums R1 R2 R3 R4
DENV1 0.94 ± 0.05 0.83 ± 0.06 0.64 ± 0.08 0.59 ± 0.08
DENV2 0.90 ± 0.03 0.88 ± 0.05 0.57 ± 0.06 0.42 ± 0.07
DENV3 0.82 ± 0.06 0.75 ± 0.07 0.77 ± 0.07 0.18 ± 0.08
DENV4 0.73 ± 0.05 0.55 ± 0.06 0.45 ± 0.06 0.61 ± 0.07
DENV1-4 0.83 ± 0.03 0.73 ± 0.04 0.59 ± 0.04 0.47 ± 0.04
R1 to R4, (H6-ED3-PhoA)2 dimers of serotypes DENV1 to DENV4, respectively. The
first column gives the serotype of the infecting DENV for the (+) serums. DENV1-4,
the serotype of the infecting virus could be any one of DENV1 to DENV4. The
DENV-uninfected serums were always taken as (−) serums. Each entry gives the
accuracy and associated standard error of a MAC-ELISA that used the Ri reagent
(i = 1,…, 4) as an antigen and was evaluated on the (+) and (−) serums.
Zidane et al. BMC Infectious Diseases 2013, 13:302 Page 5 of 10
http://www.biomedcentral.com/1471-2334/13/302
infected serums (column 2 of Table 5), in accordance
with the cross-reaction pattern (column 2 of Table 4).
The R3 reagent discriminated between DENV3-infected
serums and either DENV1- or DENV2-infected serums
with poor to no accuracies (column 3 of Table 5), despite
weak cross-reactions between ED3.DENV3 and the IgMs
of DENV1- or DENV2-infected serums (column 3 of
Table 4). In contrast, R3 discriminated between DENV3-
and DENV4-infected serums with a good accuracy, in ac-
cordance with the absence of cross-reactions between
ED3.DENV3 and the IgMs of DENV4-infected serums.
The R4 reagent did not discriminate between DENV4-
and DENV1-infected serums (column 4 of Table 5), des-
pite the absence of cross-reactions between ED3.DENV4
and the IgMs of DENV1-infected serums (column 4 of
Table 4). R4 discriminated between DENV4-infected ser-
ums and either DENV2- or DENV3-infected serums with
good accuracies, in accordance with the absence of cross-
reactions between ED3.DENV4 and the IgMs of such ser-
ums. A more detailed analysis of the data in Tables 4 and
5 showed that the discrimination by a given Ri reagent be-
tween homotypic DENVi- and heterotypic DENVj-infected
serums was not correlated with the discriminations by Ri
between DENVj infected serums and DENV-uninfected
serums (not shown). Otherwise stated, the Ri reagent may
not discriminate between the DENVi- and DENVj-infected
serums, even if the IgMs of the DENVj-infected serums do
not cross-react with ED3.DENVi. Conversely, the Ri re-
agent may discriminate between the DENVi- and DENVj
serums even though the IgMs of the DENVj-infected
serum cross-react with ED3.DENVi. Moreover, the dis-
crimination by the Ri reagent between DENVi- and
DENVj-infected serums was not correlated with the num-
ber of residue changes between ED3.DENVi and ED3.
DENVj (not shown). Thus, sequence differences could not
predict the discrimination between two serotypes by a
given reagent.
Additional discriminations
For each Ri reagent, we calculated its discrimination
between serums infected by any of the four DENV
serotypes (DENV-infected serums) and DENV-uninfected
serums, i.e. the set of positive serums was constituted by
all the DENVj-infected serums with j = 1, …, 4. This dis-
crimination was good for R1, fair for R2 and nil for R3
and R4 (Table 4, row 5). The discrimination between the
DENV-infected and DENV-uninfected serums by Ri was
strongly negatively correlated with the number of residue
changes between the consensus ED3 domain and the ED3.
DENVi domain (RP = 0.98; compare rows 5 of Tables 2
and 4). Thus, ED3.DENV1 behaved like a consensus ED3
domain.
For each reagent Ri (i = 1, …, 4), we calculated its dis-
crimination between serums infected by the homotypic
DENVi and serums infected by any of the three hetero-
typic DENVs, i.e. the set of negative serums was consti-
tuted by all the DENVj-infected serums with j ≠ i. This
discrimination was good for R1 and fair for R2, R3 and R4
(Table 5, row 5). We calculated its discrimination between
serums infected by the homotypic DENVi virus and ser-
ums uninfected by any DENV or infected by any of the
three heterotypic DENVj (j ≠ i). This discrimination was
excellent for R1, good for R2, fair for R3 and poor for R4
(Table 5, row 6). Thus, each Ri reagent could recognize
the homotypic DENVi-infected serums with at least some
accuracy.
Discussion
MAC-ELISA using (H6-ED3-PhoA)2 dimers
The ability to analyze the specificities and cross-reactivities
of human IgMs towards the different serotypes of the ED3
domain depends on the existence and use of a reliable test
for the interaction between IgMs and ED3 domains. Here,
we used a MAC-ELISA with (H6-ED3-PhoA)2 dimers as
antigens. The use of such antigens raised two questions:
was the ED3 domain correctly folded in these dimers and
was it accessible to antibodies? The ED3 domain has one
disulfide bond and the PhoA monomer has two disulfide
bonds. Previously, we have shown that the isolated ED3
domain can be produced in a correctly folded state in the
periplasmic space of E. coli, where the formation of the
disulfide bonds is efficiently catalyzed [71]. In particular,
site-directed mutagenesis experiments and the crystal
structures of the complexes between the ED3 domains
from the four serotypes of DENV and the scFv fragment of
the broadly neutralizing monoclonal antibody mAb4E11
have shown that the epitope of mAb4E11 is discontinuous,
conformational, and included within the ED3 domain
[29,72]. PhoA is enzymically active only as a dimer. We
Table 5 Capacity of the (H6-ED3-PhoA)2 reagents to
discriminate between serums infected by different DENV
serotypes in a MAC-ELISA
(−) Serums R1 R2 R3 R4
DENV1 na 0.52 ± 0.09 0.55 ± 0.10 0.57 ± 0.08
DENV2 0.78 ± 0.08 na 0.68 ± 0.08 0.70 ± 0.07
DENV3 0.84 ± 0.07 0.72 ± 0.08 na 0.80 ± 0.07
DENV4 0.87 ± 0.06 0.85 ± 0.05 0.81 ± 0.07 na
Other DENV 0.84 ± 0.06 0.72 ± 0.06 0.70 ± 0.06 0.69 ± 0.06
All others 0.90 ± 0.05 0.81 ± 0.04 0.73 ± 0.06 0.66 ± 0.06
R1 to R4, (H6-ED3-PhoA)2 dimers of serotypes DENV1 to DENV4, respectively; na,
non applicable. The serotype of the infecting DENV for the (+) serums was always
identical with the serotype of the reagent. The first column gives the serotype of
the infecting DENV for the (−) serums. Other DENV, all DENV serotypes except the
serotype of the reagent. All others, all serums (infected and uninfected) except
those infected by the same DENV serotype as the reagent. Each entry gives the
accuracy and associated standard error of a MAC-ELISA that used the Ri reagent
(i = 1,…, 4) as an antigen and was evaluated on the (+) and (−) serums. Note that
the expressions (+) serums and (−) serums refer to the discrimination under
statistical analysis and not to the infected or uninfected character of the serums.
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have shown that the H6-ED3-PhoA hybrids have both their
ED3 and PhoA portions correctly folded and active when
they are produced in the E. coli periplasm. This result
was obtained by measuring the specific activity of the
hybrids for the dephosphorylation of pNPP in vitro
and assaying their binding to immobilized mAb4E11
in an indirect ELISA, revealed with their intrinsic
phosphatase activity [66].
In the H6-ED3-PhoA hybrids, the C-terminal residue of
ED3 (residue 400 of the E protein) is linked to residue Val7
of the mature PhoA through a flexible linker tripeptide
Thr-Ser-Gly [66]. The (H6-ED3-PhoA)2 dimers recognize
both mAb4E11, as recalled above, and cell receptors
[41,73]. Therefore, the ED3 domain should be at least as ac-
cessible in the (H6-ED3-PhoA)2 dimers as in the full and
infectious DENV virus, where it interacts with the other do-
mains of the E protein and its C-terminal residue is linked
to the transmembrane region of the E protein and faces the
lipid membrane [74].
Thus, the (H6-ED3-PhoA)2 dimers can be directly pro-
duced in a soluble, correctly folded, multimeric state in
the periplasmic space of E. coli. They can be produced and
purified in a homogeneous state from periplasmic extracts.
They constitute self-sufficient reagents since the ED3 anti-
gen and PhoA reporter enzyme are covalently linked
within the same molecule. MAC-ELISA based on such di-
mers involve a low number of steps or manipulations. The
antigen is dimeric and therefore can bind its target
through an avidity phenomenon. Such dimers have already
been used to detect weak interactions between the ED3
domains of various flaviviruses and either cell receptors or
human IgMs [41,71,73].
Analysis of MAC-ELISAs with ROC curves
The analysis of a test with a ROC plot gives a measure
of its capacity to distinguish between two alternatives,
the positive and negative cases. A ROC plot gives the ac-
curacy (AUC) value of a test independently of the event
frequencies in the test samples and of the decision cri-
terion, i.e. threshold value. To measure the accuracies of
the MAC-ELISAs that used the (H6-ED3-PhoA)2 dimers
as antigens, it was necessary to constitute collections of
well-characterized human serum samples, i.e. serums
whose DENV-infected or uninfected status was reliably
established, whose infecting DENV serotype was known,
and which contained significant amounts of IgMs
against the infecting DENV serotype. These characteriza-
tions are described briefly in the Methods section and in
more detail elsewhere [65]. They depended themselves
on specific tests and thresholds. However, because they
were based on sensitive, well-established, standardized,
redundant methods that differed from that under
analysis, we considered the classifications of the human
serums in our collection as absolute.
An AUC value of x means that a randomly selected
serum with the properties of the (+) group has a test
value larger than that of a randomly chosen serum with
the properties of the (−) group 100x% of the time [67].
Therefore, if a MAC-ELISA with reagent (H6-ED3-
PhoA)2 can discriminate between the serums of the (+)
and (−) groups, this discrimination implies that the
interaction with the ED3 domain is “stronger” for the
IgMs of the (+) group than for the IgMs of the (−)
group, where the word “stronger” may include both con-
centration and avidity components.
Serotype cross-reactivities of human IgMs
Our results confirmed that the serums of human pa-
tients infected by DENV contain IgMs directed against
the ED3 domain [46-48]. They showed that the IgMs of
human serums infected by a given DENVi serotype
cross-reacted with the ED3 domains from other DENVj
serotypes (i ≠ j). Therefore, they extended similar obser-
vations, previously made with whole-virus antigens, to
the small ED3 domain [15-19]. They also extended simi-
lar observations, previously made for IgGs, to IgMs [75].
The exact patterns of cross-reactivities depended on the
infecting DENV serotype.
The ED3.DENVi domains could discriminate between
the IgMs of serums that were infected by the homotypic
DENVi virus and the IgMs of serums that were unin-
fected by DENV, in our MAC-ELISA assays. The levels
of discrimination varied with the serotype, in the de-
creasing order DENV1 ≥DENV2 ≥DENV3 > DENV4
(diagonal of Table 4). This conclusion on IgMs is remin-
iscent of published data on IgGs: (i) Several studies have
shown that many mouse monoclonal antibodies that are
specific for the DENV complex of flaviviruses, have af-
finities for the four serotypes of the ED3 domain and
neutralization potencies of the four serotypes of DENV
in the same decreasing order as above [25,29,76]. (ii)
The content of human serums in IgGs against DENV
after a primary infection is higher during an infection by
DENV1 and lower during infections with DENV2 and
DENV3 when assayed by an indirect ELISA with recom-
binant ED3 domains as antigens [6]. (iii) In tetravalent
strategies of immunization against dengue simultan-
eously with attenuated strains, or E proteins, or ED3 do-
mains of the four DENV serotypes, lower levels of
neutralizing antibodies are induced against DENV3 and
especially DENV4 in comparison with DENV1 and
DENV2 in mice and humans [59,62,77,78]. These com-
parisons between our results on IgMs and published
data on IgGs suggest that the AUC value might be
somehow related to the “level” or “strength” of the inter-
action between the serum IgMs and ED3 domain under
assay, in our specific experimental conditions. If such a
relation was valid, we could conclude that the serum
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IgMs reacted the strongest with ED3.DENV1 and the
weakest with ED3.DENV4, whatever the infecting sero-
type (rows of Table 4).
The R1 reagent gave the highest discrimination be-
tween serums infected by any one of the DENV sero-
types and uninfected serums. In particular, R1 gave a
discrimination equal to or higher than that of the
homotypic reagent, between serums infected by a given
DENV serotype and uninfected serums (Table 4). These
results showed that ED3.DENV1 behaved like a con-
sensus or universal ED3 domain for the detection of
IgMs directed against any DENV serotype. They were
reminiscent of published data showing that, in human
secondary infections, the serum titer in IgGs against
ED3.DENV1 is higher than those against the three
other ED3 serotypes, regardless of the infecting DENV
serotype [6].
Serotype specificities of human IgMs
We showed that some Ri reagents could discriminate be-
tween human IgMs directed against the homotypic DENVi
and IgMs against heterotypic DENVj viruses (j ≠ i). The
levels of discrimination by Ri between IgMs directed against
the two different DENV serotypes were not correlated with
the levels of discrimination by Ri between DENVj infected
serums and DENV-uninfected serums, i.e. with the profiles
of cross-reactivities. They were not correlated with the
numbers of residue changes between ED3 domains. Note-
worthily, R1 could discriminate between IgMs against
DENV1 and IgMs against DENV2, DENV3 or DENV4,
whereas R2, R3 and R4 could not discriminate between
IgMs against the homotypic DENV and IgMs against
DENV1 (Table 5). Any ED3 domain interacted more
strongly with the IgMs against the homotypic DENV than
with the IgMs against heterotypic DENVs, with one excep-
tion. Each ED3 domain interacted as strongly with the IgMs
against DENV1 as with the IgMs against the homotypic
DENV (row 1 of Table 5). Fine structural properties might
explain these discriminations between serotypes. The Ri re-
agents had also significant levels of discrimination towards
IgMs directed against the heterotypic DENVj viruses (j ≠ i),
taken as a whole (line 5 of Table 5), although not high
enough for diagnostic tests. Data on the discrimination be-
tween DENV serotypes by ED3 domains in a MAC-ELISA
had not been reported previously to our knowledge.
Conclusions
Many properties of serotype specificity and cross-reactivity
that have been reported for IgGs against the ED3 domain
of DENV, appear to pre-exist in IgMs. These properties
could thus be passed from IgMs to IgGs during the matur-
ation of the immune response.
Our study describes tools, the (H6-ED3-PhoA)2 di-
mers, and a statistical method that can be used to
characterize the early immune response against different
serotypes or strains of pathogenic flaviviruses, in particu-
lar after a vaccination and challenge. Its results for the
four DENV serotypes should help better understand the
early immune response during infections by these viruses.
These results could be useful for the interpretation of
MAC-ELISA assays that are used in the diagnosis of
dengue, and for the fine engineering of the ED3 domains
to obtain better diagnostic reagents and vaccines.
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